Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"BCR-ABL1"”.
-
Pax5 Haploinsufficiency Cooperates with BCR-ABL1 to Induce Acute Lymphoblastic Leukemia
… translocations including the t(9,22)[<em>BCR-ABL1</em>], t(1,19)[<em>TCF3-PBX1</em>], t(12,21)[<em>ETV6-RUNX1</em>], <em>MLL</em>rearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage leukemia. Each translocation confers a characteristic transforming phenotype within …
-
Multilineäre Beteiligung der Leukämogenese in der BCR::ABL1-like Akuten Lymphoblastischen Leukämie
… in der Leukämogenese ist für die BCR::ABL1-positive ALL gut beschrieben und stellt einen potenziellen Resistenzmechanismus gegenüber B-Zell-spezifischen Therapien dar. Die biologisch verwandte BCR::ABL1-like ALL ist eine Subgruppe mit bislang unzureichend erklärter Leukämogenese. …
-
Quantification of Major BCR-ABL1 Fusion Gene Transcripts for Monitoring Therapeutic Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia; Comparison of LightCycler t(9;22) Quantification Kit and BCR-ABL1 Mbcr IS-MMR Dx Kit.
… (Ph) and the corresponding fusion gene, BCR-ABL1. For disease monitoring, standardize BCR-ABL1 quantification and International Scale (IS) has been suggested, and this study is to compare IS-based IS-kit with non-IS-based LightCycler-t(9;22) Quantification kit (LC kit; Roche, Germany) for …
-
Prognostic markers associated with tyrosine kinase inhibitor treatment response and maintenance of treatment free remission in chronic myeloid leukaemia
… “halving time”, which measures the velocity of BCR-ABL1 decline with initial TKI treatment. This correlates well with future treatment response and risk of disease progression. Conversely, the treatment resistance can be measured by the speed at which the BCR-ABL1 rises, in a similar metric …
-
Molecular and functional studies of ABL1 and FGFR1 fusion oncogenes in myeloproliferative neoplasms
The tyrosine kinase encoding genes ABL1 and FGFR1 are involved in fusion genes underlying the myeloproliferative neoplasms chronic myeloid leukemia (CML) and the 8p11-myeloproliferative syndrome (EMS). CML and EMS are both myeloproliferative disorders with an initiating, relatively indolent, …
-
Ocorrência de eventos adversos relacionados a inibidores de tirosina quinase de primeira e segunda geração : revisão de literatura
… housekeeping gene of chromosome 22 producing the BCR - ABL1 fusion gene. This fusion gene is transcribed and translated into protein BCR - ABL1. The tyrosine kinase inhibitors (TKIs) act by blocking the binding of ATP at the ABL1 kinase domain inhibi ts phosphorylation and resulting in cell death. …
-
The Wilms' tumor gene 1 (WT1) and leukemia -new insights and further complexity
… partner of WT1. Our data also indicate that BCR/ABL1 induce expression of the WT1 gene via the phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway in the leukemic cell line K562. Given our finding that WT1 downregulated the expression of IRF-8, we propose that WT1 is a link between …
-
Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia
… of a primitive hematopoietic cell by the BCR/ABL1 fusion gene that is formed through the chromosomal translocation t(9;22). CML is currently successfully treated with tyrosine kinase inhibitors targeting the ABL1 kinase domain. However, the CML stem cells are insensitive to this drug and a …
-
Identification and functional characterisation of gene fusions in human cancer cell lines
… gene fusions such as EML4-ALK in lung cancer and BCR-ABL1 in chronic myeloid leukaemia have already led to changes in clinical care. However, important questions remain about the role of gene fusions in promoting oncogenic phenotypes and their relevance in drug response. In this study, I combine …
-
Rational drug combinations design against intratumoral heterogeneity and clonal evolution
… in giving rise to resistance to clinically used BCR-ABL1 inhibitors. Remarkably, the resistant population also became hyper-sensitized to nonclassical BCR-ABL1 inhibitors at intermediate stages of the clonal evolution, in this so-called 'temporally collateral sensitivity'. Mathematical modeling …
-
Die Rolle der Zinkfingerproteine ZFP36L1 und ZFP36L2 und ihrer Targets in der Imatinib-Resistenz in der chronischen myeloischen Leukämie
… Imatinib-Resistenz haben. Zur Untersuchung von BCR::ABL1-unabhängigen Resistenzmechanismen wurde ein in vitro-Resistenzmodell etabliert, in dem unbehandelte K-562 CML-Zellen gegen Imatinib resistent gezüchtet wurden. In diesen Imatinib-resistenten Zellen war ein signifikanter Anstieg der …
-
Co-optation of B Cell Developmental States in Malignancy and Autoimmunity
… to dysregulated cell-intrinsic signaling in BCR-ABL1 B cell acute lymphoblastic leukemia (B-ALL), cell-extrinsic signaling in CTLA4-deficient T cell-mediated follicular B cell blocks, and integrative mutational and niche-specific survival in mantle cell lymphoma (MCL). Finally, we identify …
-
Computational and experimental methods for CRISPR-based saturation mutagenesis screens
… in situ saturation mutagenesis of the BCR-ABL1 oncogene to identify drug resistant variants and IRF1 untranslated region (UTR) to map non-coding regulatory elements involved in transcriptional initiation.
-
An in vivo RNAi therapy screen identifies novel mediators of leukemia-microenvironment interaction
… target and eradicate minimal residual disease. BCR-ABL1+ BCP-ALL is an aggressive subtype of BCP-ALL, and despite the use of tyrosine kinase inhibitors (TKIs) as additional therapeutics that directly inhibit BCR-ABLI, more than half of BCR-ABLI+ BCP-ALL patients will experience a relapse. We …
-
WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?
… is induced by tyrosine kinase signalling from BCR/ABL1 via the PI3K/Akt pathway. Chronic myeloid leukemia (CML) cells with forced expression of WT1 showed enhanced resistance to apoptosis induced by the ABL1 tyrosine kinase inhibitor, imatinib, further proposing an oncogenic function for WT1. …
-
Genomics, Diagnosis, Novel Targeted Therapies and Characterisation of the Drivers of Relapse in Philadelphia Chromosome-Like Acute Lymphoblastic Leukaemia
… thesis focuses on Philadelphia chromosome-like (BCR::ABL1-like) acute lymphoblastic leukaemia (Ph-like ALL), a subtype of B-cell ALL recently recognised as a distinct entity. The genomic drivers of Ph-like ALL are diverse. This thesis emphasises investigation of the JAK/STAT class of lesions. …
-
Developing Targeted Therapies for T-cell Acute Lymphoblastic Leukemia
… showed strong response to dasatinib, a known ABL1 inhibitor. Importantly, none of the T-ALL responders harbored BCR-ABL1 or fusions predicted to respond to ABL1 inhibitors. We identified differences in somatic genetic alterations between dasatinib responders and non-responders. For example, as …